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Abstract
Platelet-rich plasma (PRP) is a biological therapy that uses the patient’s own 
blood to obtain products with a higher platelet concentration than in blood. It 
provides a transient fibrin scaffold as a controlled drug delivery system of growth 
factors suitable for regenerative medicine. PRP has been used as medical strategy to 
treat diverse types of injuries in the field of orthopedics, including peripheral nerve 
lesions. In vitro and in vivo studies showed the neuroprotective, neurogenic and 
neuroinflammatory modulator effect of PRP. In addition, it has been demonstrated 
clinically that PRP infiltrations improve clinical symptoms and enhance the sensory 
and motor functional nerve muscle unit recovery. Potential effects of PRP could 
be applied in treatments for neuropathies, as conservative treatment by means of 
nerve ultrasound-guided infiltrations or as biological adjuvant during surgery.
Keywords: platelet-rich plasma, growth factors, neuropathies, intraneural injection, 
perineural injection, US-guided injection
1. Introduction
Diverse health conditions or traumatic injuries such as accidents, stretching or 
compressions may cause damage on nerves. Some options to treat these damages are 
oral drugs, steroid injections, physical therapy or surgical interventions. Probably, 
nerve autografts or direct tension-free microsurgical repairs are the most common 
treatments aimed to enhance the intrinsic regenerative potential of injured axons. 
However, they do not recreate the suitable cellular and molecular microenviron-
ment of peripheral nerve repair.
To overcome this drawback, new therapeutic strategies have been developed for 
these conditions, using various models of nerve injuries. In vitro models of neuro-
nal survival include cell cultures or tissue engineering advances, whereas in vivo 
models involve lesions in peripheral nerves of many species. These studies lead to 
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develop new strategies based on tissue engineering approaches through molecular 
intervention and scaffolding, and platelet-rich plasma (PRP) represents one of these 
promising biological strategies. Large number of studies provides evidence for PRP 
application in musculoskeletal disorders and orthopedics. Applications include treat-
ments of chondropathy, osteoarthritis, tendinopathy, muscle or ligament tear, acute 
and chronic soft tissue injuries, as well as enhancement of healing after bone or tissue 
reconstruction [1]. In addition to its positive effects on the healing of many types of 
tissues, recent studies reported the promising effects of PRP on nerve regeneration 
[2]. Indeed, several preclinical and clinical studies have proved the neuroprotective, 
neurogenic and neuroinflammatory properties of this therapy. Moreover, pain reduc-
tion, function improvement and nerve-muscle unit recovery have been demonstrated 
after applying diverse PRP formulations including liquid and scaffold form. This 
chapter is intended to overview the advances made on this specific field, focusing on 
the concept of PRP, its biological effects on nerve repair and its clinical application.
2. Platelet-rich plasma
PRP is an autologous product with a higher platelet concentration than in blood. 
It consists of a pool of bioactive mediators including growth factors (GF), cytokines, 
microparticles and others from patient’s own blood. Currently, there are several 
methods and commercial devices to achieve PRP, obtaining a diversity of products 
including autologous conditioned plasma, platelet-enriched plasma, platelet-rich 
concentrate, autogenous platelet gel, platelet releasate, platelet rich in GFs and others 
[3]. Some parameters and characteristics such as platelet concentration, the presence 
of leucocytes or the fibrin architecture may vary depending on the method or device 
employed to obtain these refined products. The processing technique to achieve PRP 
mostly consists of a blood collection in the presence of an anticoagulant followed by 
centrifugation. This centrifugation separates the blood components with the aim of 
discarding substances considered as not usable such as red blood cells and concentrat-
ing the elements with therapeutic potential, for instance fibrinogen/fibrin, platelets or 
GF, with or without leukocytes (Figure 1). Before its administration, an activating fac-
tor such as thrombin or calcium is added to the platelet concentrate to promote platelet 
degranulation and exocytosis of the factors stored in the cytoplasmic granules [4].
Indeed, the potential effect of PRP is closely related with the release of bioactive 
molecules stored in alpha granules of platelets after its activation with the activat-
ing factor [5]. Platelet-derived growth factor (PDGF), transforming growth factor 
(TGF-β), epidermal growth factor (EGF), insulin-like growth factor (IGF-1), 
hepatocyte growth factor (HGF), basic fibroblasts growth factor (FGF) and vascu-
lar endothelial growth factor (VEGF) are some of the key proteins associated with 
the acceleration of healing process, since they modulate angiogenesis, remodel the 
extracellular matrix (ECM) and affect the recruitment, proliferation and differ-
entiation of stem cells [6]. The wide variety of elements found in platelet granules 
act synergistically under normal physiological conditions on local cells to promote 
wound healing. On the other hand, plasma activation also promotes the polymeriza-
tion of fibrinogen into a three-dimensional fibrin scaffold (Figure 1), maintaining 
the bioactive mediators trapped through fibrin heparin sulfate-binding domains 
[1]. This biocompatible and biodegradable scaffold provides plastic-elastic stiffness 
and generates GF gradients that are essential cues for cell proliferation, differentia-
tion, migration and correct orientation in the nascent tissue [7]. When fibrinolysis 
begins, a gradual, sustained release of GF and other biomolecules occurs, in contrast 
to a bolus delivery modality. Thus, this technology provides a fibrin scaffold as a 
controlled drug delivery system of GF suitable for regenerative medicine [8].
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Due to its primarily autologous origin and relatively noninvasive collection 
technique, the risks of injection or immune rejection associated with PRP are mini-
mized, making this biological therapy a powerful tool for its application on diverse 
medical fields. Thus, this strategy has been employed as a biological adjuvant in 
peripheral nerve injuries and neuropathies, enhancing the sensory and motor 
functional nerve-muscle unit recovery [9]. In cases of nontraumatic peripheral 
injuries such as compression, adhesion and/or fibrotic postsurgical side effects, PRP 
may help diminish undesirable consequences such as denervated organ atrophy and 
fibrotic scars.
3. Biological effects of PRP on nerve regeneration
Among therapeutic alternatives to restore damaged nerves, PRP is gaining 
attention, since it provides the infiltrated environment with a pool of GF inducing 
healing and regeneration of the tissue. Nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF) and PDGF are some of PRP components that can 
improve nerve regeneration. However, a sustained delivery of several GFs is not the 
unique constituent of PRP effect on nerve regeneration. Indeed, in vitro and in vivo 
evidence suggests that the biomolecules transmitted by PRP are instrumental agents 
that act as key drivers of full nerve functional recovery, offering a new possibility 
for nerve regeneration (Figure 2).
Figure 1. 
Platelet-rich plasma formulation. After withdrawing a small volume of venous blood in tubes containing 
anticoagulant, these are centrifuged in order to separate the blood components. The plasma fraction located just 
above the red blood cells is collected including or not leukocytes. PRP is activated adding thrombin or calcium to 
promote platelet degranulation and exocytosis of GF. This liquid formulation is used to conduct PRP injections. 
If after activation, the waiting time is prolonged, fibrin formation is achieved, obtaining a scaffold for applying 
in surgery.
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3.1 Neuroprotection and prevention of cell apoptosis
An important factor that plays a critical role in many functions within the ner-
vous system including neurogenesis and neuroprotective function is BDNF. One 
of the most important benefits that this biomolecule offers is its ability to inhibit 
neuronal and glial apoptosis after traumatic injury. A work carried out by Koda 
et al. proved that BDNF suppressed in a dose-dependent manner anoikis of 
Schwann cells (SC), which are able to promote axonal regeneration and func-
tional recovery [10]. This effect is based on the activation or transdifferentiation 
of SCs, a drastic modification of the phenotype of this cell type that takes place 
after the disruption of the regeneration unit by the noxious agent. Macrophages 
will collaborate with the activated SCs clearing the myelin and other tissue 
debris. Moreover, these SCs come into direct contact with resident fibroblasts 
accumulated in large numbers at the site of injury, influencing SC migration 
and transdifferentiation. In another work, Wang et al. found that mesenchymal 
stem cells (MSCs) transfected with Ad-BDNF enhance the expression of BDNF, 
recovering brain damage. They suggest that BDNF-MSCs have a potential protec-
tive effect against neuron death by apoptosis [11]. In another study, Zurita et al. 
enriched PRP fibrin scaffolds with bone marrow stromal cells with BDNF, NGF 
and retinoic acid, enhancing cell survival and differentiation into the neural 
phenotype [12]. Another GF related with neuronal and Schwann cell survival is 
IGF-1. This factor acts as neurotrophic factor for sensory, motor and sympathetic 
neurons to promote growth cone motility and prevent apoptosis [13]. It has also 
been proved that neurons express PDGF receptors, and the function related with 
this GF on nerve injury also involves the survival for Schwann cells with trophic 
activity on neurons [14]. Other substances such as NGF, FGF, VEGF and TGF-β 
presented in PRP have shown to exert an antiapoptotic and neuroprotective effect 
on diverse cell types such as MSCs, neurons, Schwann cells and human neural 
stem cells [15].
Figure 2. 
Effects of PRP on nerve repair. Biomolecules and GF participate jointly and synergistically in several biological 
processes involved in nerve regeneration.
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3.2 Anti-inflammatory effects
Anti-inflammatory action of PRP is associated with an inhibition of nuclear 
transcription factor-kB (NF-kB) pathway, which was observed after culturing 
astrocytes with PRP supernatants [16]. Some of the GFs such as HGF, IGF-1, PDGF 
and TGF-β delivered in a sustained way after PRP infiltrations are closely related 
with these effects [15]. TGF-β also affects cellular behavior, the neurite outgrowth 
and glial scar formation [17]. Outcomes from an in vivo study further suggested 
that TGF-β coordinated with adipose-derived MSCs enhanced nerve regeneration 
affecting the host’s immune response and reducing inflammation [15].
PRP injections have been associated with a decrease of proinflammatory sub-
stances such as nitric oxide, cyclooxygenase and tumor necrosis factor expressed in 
the brain [16]. In addition, PRP is able to block Ab-induced upregulation of proin-
flammatory cytokine production, and this capacity was correlated with a preven-
tion of the decrease in several synaptic proteins.
3.3 Angiogenic properties
Among the substances that PRP contains, VEGF is one of the most angiogenic fac-
tors. It stimulates proliferation and migration of endothelial cells, formation of new 
blood vessels and enhances vascular permeability. This action is conducted by trans-
membrane receptors found in neural tissue, especially on growth cones of sprouting 
axons and Schwann cells [18]. VEGF can act as a neurotrophic factor by promoting 
Schwann cell proliferation and neurite outgrowth and enhance nerve survival [19]. 
However, despite the evidence that PRP promotes angiogenesis in tendon, muscle 
and bone and the crucial role that blood vessels play as trackers of the axonal growth 
cones across the injury site, there is lack of studies assessing angiogenesis in nerve 
repair. Borselli et al. showed that an injectable scaffold loaded with VEGF and IGF-1 
accelerated regeneration of damaged neuromuscular junction innervation together 
with an enhancement of angiogenesis in an ischemic limb rodent model [20]. Another 
study demonstrated that vein graft filled with PRP provides an earlier and more 
prominent neoangiogenesis than sciatic nerve gaps treated with nerve autograft alone 
[21]. The fibrin obtained after PRP activation provides a permissive and robust 3D 
matrix for angiogenesis. In fact, autologous fibrin matrix is the best tailored transient 
scaffold for tissue regeneration where complex morphogenetic processes for tissue 
regeneration take place, including angiogenesis, cell migration and proliferation [22].
3.4 Enhancing axonal outgrowth capacity
Schwann cells provide bioactive substrates for axonal migration and they release 
neurotrophic factors able to regulate axonal outgrowth. An optimal proliferation 
and viability may affect the rapid regeneration of injured peripheral nerves. PRP 
might allow the sprouting of growth cones since they promote survival, prolifera-
tion and differentiation of Schwann cells. In that sense, Zheng et al. showed a 
dose-dependent effect of PRP on the proliferation, migration and neurotrophic 
function in rat Schwann cells cultured with PRP [23]. The significant role played by 
GF within the PRP has also been highlighted in a rat brain-spinal cord cocultured 
system, where the addition of PRP supernatant promoted an increase in the size and 
number of axons. This positive effect was significantly suppressed by the addition 
of antibodies against IGF-1 and VEGF [24].
Solid form of PRP also demonstrated its positive effect on both axonal myelina-
tion and its density enhancement. Ye et al. fabricated tissue-engineered nerves 
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based on poly (lactic-co-glycolic acid) conduit using PRP gel for suspension of 
Schwann cell–like cells. PRP group presented superior functionality in both nerve 
conduction velocity and compound muscle action potential. They suggest that 
PRP gel plays a dual role: first, the fibrin network as matrix for regenerative cell 
incorporation, and second, biomolecules that improve the biological environment 
stimulating the regenerative processes of nerve fibers [25]. Indeed, the PRP bioac-
tive proteins initiate and control the healing cascade of nerve fibers. Increasing the 
concentration of these bioactive proteins such as TGF-β, PDGF and IGF-1 could 
accelerate healing of the regenerating nerve fibers [26]. Other studies realized 
in rabbits after implantation of PRP together with Schwann cells [27] reported 
beneficial effects on axonal counts, myelination and electrophysiological param-
eters. Cho et al. observed considerably increased expression of neurotrophic factors 
such as BDNF, NGF, FGF and Glial cell–derived neurotrophic factor (GDNF) after 
PRP injection in guinea pigs with facial nerve transection, suggesting that PRP and 
MSCs act as a source of neurotrophic factors. They also could prove an enhance-
ment of axon counts and myelination in the groups treated with PRP [27]. An 
inside-out vein autograft filled with PRP was used to bridge a 10-mm-long sciatic 
nerve defect in rats [21]. The axon diameter, the number of myelinated axons and 
myelin sheath were significantly superior when vein autograph was filled with 
PRP. In another rat model, they used platelet-rich fibrin (PRF) as a filler of silicon 
nerve guidance. Animals treated with PRP improved functional recovery and 
showed a superior sciatic functional index compared to nontreated animals [28].
3.5 Dampening the denervated target muscle atrophy
The acceleration of axonal growth can prevent muscle atrophy, since it reduces 
the time to establish a connection between the sprouting axon and target muscle 
[29]. PRP applications induce an earlier axonal regeneration and functional recovery, 
which also can have a consequence reducing the target muscle atrophy. In the work 
carried out by Sánchez et al., they could observe this positive effect since nerves 
repaired with intraneural infiltrations of PRP were associated with lower muscle 
atrophy and an earlier electrophysiological recovery [30]. In some peripheral nerve 
injuries such as carpal tunnel syndrome or fibrotic postsurgical side effects, the main 
pathological agent is compression, adhesion and/or fibrosis. The use of PRP may addi-
tionally avoid or at least diminish denervated organ atrophy and undesirable fibrotic 
scars, thereby accelerating the functional recovery of the nerve-muscle unit, due to its 
antifibrotic effects [24, 31]. Intramuscular injection of PRP 24 hours after the induc-
tion of limb ischemia in mice mitigated fibrosis and muscle atrophy [32]. These results 
are in agreement with the reduction of atrophy in denervated muscle reported when 
muscle was infiltrated with cells [33], effects suggested to be mediated by IGF-1 [34].
4. Clinical guidelines for the application of platelet-rich plasma in 
injured peripheral nerves: from bench to bedside
Although the biological effects described previously mean a promising thera-
peutic tool, the success to achieve optimal clinical results lies in several factors such 
as PRP preparation, dosage and application protocols.
4.1 PRP preparation
Physicians face a large number of systems to obtain PRP and therefore 
different types of final products. These depend on variables such as platelet 
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concentration, the presence or absence of leukocytes and the exogenous activation 
of PRP. Although there is still no consensus on which is the best product to use in 
orthopedic pathologies, according to preclinical research and our experience, we 
suggest choosing a product with specific characteristics.
An excessive number of platelets could not only suppress the therapeutic action 
of PRP but also inhibit the tissue repair process. PRP with excess platelet concentra-
tion had negative influence over cellular responses such as proliferation, viability or 
differentiation [35]. Thus, it seems that a concentration of platelet slightly higher 
than blood is suitable to achieve an optimal response. The presence of leukocytes 
in PRP products is more controversial. While in tissues like cartilage the scale tips 
in favor of the PRP without leukocytes, in other applications, it is not clear. The 
presence of leukocytes fosters the nuclear NF-κB p65 protein expression, which is 
key in the activation of cellular inflammation, and oddly enough, it is inhibited by 
PRP [36]. Finally, and although platelets within PRP can be activated endogenously 
by tissue collagen, we recommend the previous activation in an exogenous way, 
which is carried out by adding calcium to PRP. As calcium was chelated during 
blood extraction to avoid coagulation, we restore the levels of it in PRP preventing 
hypocalcemia in nerve environment during infiltration. The activation triggers the 
formation of a fibrin 3D liquid scaffold that spreads over the tissue, delivering GF 
in a control manner. After activation, PRP must be injected immediately during the 
following 10 minutes. Without activating, it can be stored for 3–4 hours without 
losing its efficacy. PRP can be applied also as a fibrin scaffold for using in surgery. 
This scaffold is obtained in the same way as the liquid formulation, except that after 
its activation, the waiting time before its use is prolonged until the formation of 
the fibrin scaffold (Figure 1). Despite these recommendations, it is in the hands of 
the professional who applies PRP to choose the best suitable type, and following the 
manufacturer’s protocol is advisable to obtain an optimal product.
4.2 Conducting nerve infiltrations
In order to achieve the biological effects described in Section 3, PRP must be 
administered in an adequate manner to reach the target tissue and cells that are key 
elements in nerve repair process such as Schwann cells. However, they are in the inner-
most compartment of the nerve, inside the fascicles that enclose the axons covered by 
the myelin sheaths, and getting to them is a major issue. For many years, nerve infil-
tration has been and still is a controversial point for physicians and medical specialists. 
Although a possible cause of nerve lesions during an injection is the ischemic damage 
due to increased pressure inside the nerve, the most likely reason is the neurotoxic-
ity of the injected drug such as corticosteroids or local anesthetics. Several studies 
demonstrated that the injuries caused to the nerve after infiltrations were because of 
the injected drug or its dose, and not because of the physical act of infiltrating [37].
The compartment of the nerve where the injection is performed is also a sensi-
tive point to consider. Although some studies recommend avoiding intraneural 
injection due to high risk of nerve lesion [38], it is necessary to be more precise in 
this description. We must distinguish between extrafascicular and intrafascicular 
injection, the former being safe and without any evidence of nerve injury [39]. 
In contrast, some studies conclude that the main cause of neurologic injury is the 
intrafascicular injections [40]. Brierley et al. studied the progression of nerve 
lesions in some diseases like tetanus or poliomyelitis using radioactive phosphorus. 
He found that the phosphorus reached the blood stream, the cerebrospinal fluid 
and the nervous system when the needle penetrated into the fasciculus, thus being 
an intrafascicular injection [41]. Diffusion studies of PRP into the nerve carried 
out by our group showed that PRP previously stained with methylene blue was 
Demystifying Polyneuropathy - Recent Advances and New Directions
8
accumulated around the perineurium after intraneural but not intrafascicular injec-
tions, without reaching inside the fascicle through the perineurium [2] (Figure 3).
4.3 Conservative treatment with US-guided infiltrations of PRP
Throughout this section, we will describe the procedures to perform US-guided 
infiltrations of PRP in some nerves susceptible to peripheral lesions, namely 
median nerve (Figure 4), ulnar nerve (Figure 5) and common peroneal nerve 
(Figure 6). The infiltrations of the nerves mentioned in this section share a large 
number of key points, which are described below. The details of each nerve are 
shown in Table 1.
4.3.1 Key points for common US-guided neural infiltrations
a. Preparation of the sterile field is required to maintain aseptic conditions 
throughout the treatment. The skin covering the affected nerve and the trans-
ducer of the US machine must be prepared following standard asepsis protocols.
b. Prior to the infiltrations, the nerve must be located by means of US in the perti-
nent areas. During this step, the US probe can be used in a long- as well as short-
axis in respect to the nerve so that its examination can be as accurate as possible.
c. In the course of PRP injections, the needle is placed parallel to the US probe, and 
consequently its orientation in respect to the nerve has influence on the PRP dif-
fusion. With the transductor in the long-axis in respect to the nerve, the needle is 
introduced almost parallel to it, spreading PRP along the nerve. If the US probe is 
placed in the short-axis, the needle is inserted at right angles to the nerve increas-
ing the risk of injury axon. The spread is less than in the previous case, especially 
when the diameter of the nerve is large. However, this approach allows better 
visualization of the tissue. Therefore, we recommend using the US transductor 
that achieves a balance between diffusion and nerve visualization.
Figure 3. 
Nerve infiltration. During the procedure, two injections are conducted. First, intraneural infiltration  
(A) reaches the intrafascicular epineurium (2) and next, the perineural infiltration (B) is performed around 
the nerve. 1 = epineurium; 2 = intrafascicular epineurium; 3 = perineurium; 4 = fascicle; 5 = endoneurium; 
6 = axon covered by myelin.
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Figure 4. 
Median nerve infiltration. The median nerve is located by means of US in the area of the wrist (A). Under US 
control with the probe placed in long-axis, the nerve (blue) is observed above the epiphyses of the distal radius 
(red) and lunate bone (white) (B). The needle (green) is inserted in distal-proximal direction, and PRP is 
injected in an intraneural (yellow) and perineural way (asterisk) (C).
Figure 5. 
Ulnar nerve infiltration. The ulnar nerve is located by means of US in the area of the elbow (A). Under US 
control with the probe placed in long-axis, the nerve (blue) is observed above the epicondyle (white) (B). The 
needle (green) is inserted in distal-proximal direction, and PRP is injected in an intraneural (yellow) and 
perineural way (asterisk) (C). In this case, the injection could be conducted in proximal-distal direction if the 
access is difficult.
Figure 6. 
Common peroneal nerve infiltration. Two approaches are possible to infiltrate common peroneal nerve. In 
the first approach, the nerve (blue) is located by US above the popliteal fossa with the US transductor in the 
long axis (A and B). In the second approach, the nerve is located in the lateral side of the knee (D). With the 
probe placed in the short axis, the nerve (blue) is observed above the peroneal head (white) and close to tibialis 
anterior muscle (red) (E). In both cases, the needle (green) is inserted in proximal-distal direction, injecting 
PRP in an intraneural (yellow) and perineural way (asterisk) (C and F).
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d. The proximal-distal direction is preferable so that PRP spreads through the 
nerve. In some cases as injections into ulnar nerve, the direction can also be from 
distal to proximal zone if the injured area is unapproachable.
e. Both intraneural and perineural injections are performed during the treatment. 
Activated PRP is injected softly and without rough movements of the needle 
to prevent nerve damage. As the PRP volume required for both infiltrations 
can exceed the capacity of the syringe, changes of syringes for loading them 
with PRP can be done without removing the needle from the injection site, thus 
avoiding repeated punctures.
f. Firstly, it is advisable to perform the intraneural infiltration with the needle 
reaching the intrafascicular epineurium of the nerve. During intraneural injec-
tion, PRP shows some hyperechoic signals under US control within the nerve.
g. Once intraneural injection is accomplished, the needle is gently retreated plac-
ing it just above the nerve to conduct the perineural injection around the nerve. 
The adjacent tissue to the nerve is detached when perineural infiltration is per-
formed, appearing as a hypoechoic signal. This infiltration entails a hydrodis-
section that reduces nerve entrapment through a mechanical effect [42].
h. The dosage of these treatments is determined by the nerve size to be infiltrated, 
which is detailed in each case (Table 1). In all cases, it is recommended to carry 
out two treatments, with an interval of two between both visits.
Median nerve Ulnar nerve Common peroneal nerve
Approach 1 Approach 2
Indication Compressive 
neuropathies such 
as CTS
Compressive 
neuropathies such 
as UTS
Nerve lesions associated to knee injuries
Patient 
position
Sitting with the arm 
flexed and supported 
on flat surface
Supine position Prone position Lateral position 
over the healthy 
side
Limb 
position
Supination, the palm 
of the hand facing 
upward
Pronation, with 
the elbow lightly 
flexed and on a 
padded support
Extended leg Lightly knee 
flexion and on a 
padded support
Infiltration 
area
Wrist, around the 
distal area of the 
radius
Behind medial 
epicondyle, into 
cubital tunnel
Back of the 
thigh, around the 
popliteal fossa 
above the knee
Lateral knee 
area around the 
peroneal head
Syringe Luer-Lok, 3 mL Luer-Lok, 3 mL Luer-Lok, 5 mL Luer-Lok, 5 mL
Needle 23 G/25 mm 23 G/25 mm 21 G/50 mm 21 G/50 mm
Direction Proximal-distal Both Proximal-distal Proximal-distal
Intraneural 
vol.
2 mL 3 mL 3 mL 3 mL
Perineural 
vol.
4 mL 6 mL 6 mL 6 mL
CTS, carpal tunnel syndrome; UTS, ulnar tunnel syndrome; Vol, volume.
Table 1. 
Characteristics of platelet-rich plasma US-guided infiltrations for different nerves.
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i. The follow-up is conducted 4 weeks after finishing the treatment. Clinical 
examination is required in order to observe improvement in clinical parameters 
such as pain and paresthesia. Depending on the patient’s condition, we will fol-
low different recommendation:
• If the patient shows a significant improvement, no intervention will be per-
formed. Six weeks after clinical follow-up, an electromyography (EMG) will 
be conducted to evaluate the state of the nerve and assess possible actions.
• When the patient evolution has flat-lined or is not enough, neural infiltrations 
with PRP will be repeated again.
• In case the patient has not experienced any improvement, infiltrations of PRP 
will be discarded and other treatment alternatives will be considered. An EMG 
study should be performed in the third month.
4.3.2 Subgluteal sciatic compression
a. PRP infiltrations into this nerve are indicated for compressive neuropathies such 
as pyramidal syndrome or deep gluteal syndrome.
b. The patient is placed as in the case of the sciatic nerve approach, namely in prone 
decubitus on a flat surface.
c. By means of US control, the nerve is located at the level popliteal fossa, and then 
the nerve path is followed until gluteal fold, where PRP injection in distal-proximal 
direction is conducted. If the nerve can be located in a more proximal area, the 
infiltration can also be performed following the proximal-distal direction.
d. The injection is conducted with 10 mL in a syringe fitted with an 18 G and 75 mm 
needle and US probe placed in the long axis.
e. Four ml of activated PRP is administered during intraneural infiltration and 
8 mL of activated PRP is infiltrated around the nerve.
4.3.3 Neuromas
Traumatic neuroma follows different forms of nerve injury often as a result 
of surgery. They occur at the end of injured nerve fibers as a form of ineffective, 
unregulated nerve regeneration. Due to the peculiarities of these neuropathies, the 
volume of the product, the type of syringes and needles to infiltrate the PRP will 
largely depend on the nerve where the neuroma is located, which was described 
above. In addition, not only an intraneural and a perineural injection into neuroma 
are conducted but also in the proximal nerve close to the neuroma.
4.4 PRP as adjuvant in surgery
In many cases, surgical interventions are required for the treatment of neuropa-
thies. Among these, the neurolysis is a standard procedure to separate the nerve 
from the surrounding tissues and try to solve problems related to compression and 
entrapment. In these cases, the use of PRP as a therapeutic adjuvant during surgery 
can stimulate and accelerate nerve recovery. Next, both endoscopic (Figure 7) and 
open neurolysis (Figure 8) of a median nerve are explained. Neurolysis in other 
nerves will be done in the same way but adapting to the particularities of each nerve.
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4.4.1 Endoscopic neurolysis
a. After performing a small incision at the level of wrist crease, a cannula is intro-
duced in order to observe structures in the wrist as the transverse carpal liga-
ment with an endoscopic camera.
Figure 7. 
Endoscopic neurolysis of median nerve. Endoscopic camera and cannula are introduced into the wrist (A). 
Carpal ligament (asterisk) is dissected and cut (B). PRP is infiltrated into the nerve (C) and a fibrin clot is 
placed between the nerve and the ligament (D).
Figure 8. 
Open neurolysis of median nerve. Median nerve and the transverse carpal ligament are observed after incision 
(A). Once median nerve is released, PRP is injected (B). Finally, fibrin membrane (C) is placed between the 
nerve and the ligament (D).
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b. When the transverse carpal ligament is located and dissected, it is cut with 
endoscopic knife so that the median nerve is released.
c. Once the ligament is sectioned and nerve released, 2 mL of PRP is infiltrated into 
the nerve from the incision made for arthroscopy with a 30 G needle. A fibrin 
clot is placed in the open carpal tunnel before suturing.
4.4.2 Open surgical neurolysis
a. An incision at the level of wrist crease is conducted. The incision must be large 
enough to observe and access to the median nerve and the transverse carpal 
ligament.
b. Next, the median nerve and the transverse carpal ligament are located and dis-
sected. During the surgery, the median nerve is released by cutting the trans-
verse carpal ligament and removing all the adhesions present along the nerve.
c. Finally, intraneural and perineural injections of PRP are performed. In addition, 
a fibrin membrane is placed between the nerve and the ligament, to later suture 
the incision.
5. Clinical results of PRP application for peripheral nerve injury
PRP products present a number of features that are quickening the application 
of this therapy in clinical practice, namely ease of use, reasonable biosafety and 
great versatility. Therefore, and although the PRP is still a recent technique, several 
clinical studies have emerging in the last decade (Table 2).
5.1 PRP infiltrations as conservative treatment
As in other pathologies, pain is one of the main problems of patients who suffer 
from peripheral nerve injuries. PRP showed to be a promising therapeutic tool for 
the relief or reduction of pain associated with neuropathies. Malahias et al. con-
ducted a case series study where patients who suffered from carpal tunnel syn-
drome (CTS) were treated with one PRP US-guided injection around the median 
nerve [43]. At 3 months of follow-up, the pain was significantly alleviated in 11 out 
of 14 patients according to VAS score. A prospective controlled study carried out 
by Uzun et al. demonstrated the effectiveness of PRP in reducing the pain associ-
ated with CTS after one perineural injection of 2 mL of PRP [44]. These kinds of 
interventions were conducted not only over the median nerve but also over the 
ulnar nerve. Patients with peripheral neuropathy associated to leprosy received a 
perineural injection of 1 mL of PRP in the posterior tibial nerves and in the ulnar 
nerve. The results of this randomized control clinical trial showed a pain decrease 
2 weeks after treatment [45].
These results are also accompanied by a functional and clinical improvement, 
which has a positive impact on the quality of life of patients. Some of the patients 
mentioned above showed functional recovery together with reduction in pain 
[42, 43]. More clinical studies also showed improvement in clinical and functional 
symptomatology when applying PRP in different peripheral nerve lesions. Recently, 
a randomized clinical study demonstrated better functional outcomes in patients 
with mild to moderate CTS [46]. Patients who received one US-guided infiltration 
of PRP into the carpal tunnel achieved a better response that patients treated with 
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saline 12 weeks after treatment. However, in this study, no differences in pain scores 
were found. A case report that described a 6-year-old boy with perinatal cerebral 
palsy should be noted [49]. After receiving an intravenous injection of 25 mL of 
PRP, an improvement in the cognitive sphere and language during the follow-up at 
3 and 6 months was observed. Levels of GF maintained stable in plasma 3–5 times 
higher than average for his age group.
It must be taken into consideration that some variables may have a certain 
subjective component or be influenced by other factors than the treatment admin-
istered. Thus, it is advisable to analyze more objective variables such as EMG. A 
randomized controlled study showed improvement in EMG parameters, such as 
sensory nerve action potential (SNAP) in CTS patients [48]. However, there were 
Reference Condition Target Intervention Improvement
Infiltrations
[43] CTS MN US-guided perineural injection  
(1 × 1–2 mL)
Pain and 
function
[44] CTS MN Perineural injection (1 × 2 mL) Pain and 
function
[45] Leprosy 
peripheral 
neuropathy
PTN and 
UN
Perineural injection (1 × 1 mL) Pain
[46] CTS MN US-guided perineural injection  
(1 × 1–2 mL)
Function
[47] Perinatal 
cerebral palsy
Systemic Intravenous injection (1 × 25 mL) Function
[48] CTS MN Injection at the distal carpal 
crease (1 × 1 mL)
Pain, function 
and EMG
[49] CTS MN US-guided perineural injection 
(1 × 3 mL)
Pain, function 
and EMG
[50] CPN palsy CPN US-guided intraneural/perineural 
infiltrations (13 × 3–8 mL)
Pain, function 
and EMG
[51] CTS MN US-guided perineural injection 
(2 × 5 mL)
Pain, function 
and EMG
[52] Section of RN RN US-guided intraneural injections 
(5 × 4 mL)
Function and 
EMG
Surgery
[53] Nerve gaps in 
extremities
Nerves 
of the 
extremities
Nerve gap bridged with a collagen 
tube with PRP fibrin
Function
[54] Persistent 
pudendal 
neuralgia
PN Injection after a transgluteal 
decompression
Function
[55] Benign parotid 
gland tumor 
with facial 
muscles and 
nerve deficit
FN PRP gel was applied around 
nerve endings during superficial 
parotidectomy
Function
CPN, common peroneal nerve; CTS, carpal tunnel syndrome; EMG, electromyography; FN, facial nerve; MN, median 
nerve; PRP, platelet-rich plasma; PTN, posterior tibial nerve; RN, radial nerve; UN, ulnar nerve; US, ultrasound.
Table 2. 
Clinical research of PRP application for peripheral nerve injury.
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no differences between control group (splint) and PRP treatment. This could 
be because the infiltration performed in this study was conducted without US 
guidance or directly into the median nerve but in adjacent areas, hampering the 
biological effects of PRP on the nervous tissue. Wu et al. carried out other random-
ized controlled study of CTS patients achieving an enhancement in sensory nerve 
conduction velocity (SNCV) and distal motor latency (DML) [49]. Although these 
EMG values were not significantly better than control group, there were significant 
differences in terms of pain and other clinical symptoms. The authors observed 
this improvement 6 months after one US-guided injection of 3 mL of PRP in the 
median nerve. In a case report described by Sánchez et al., a patient with peroneal 
nerve palsy underwent serial US-guided intraneural and perineural injections for 
33 months [50]. The patient not only achieved improvement related to pain and 
function but also showed EMG sings of reinnervation for the peroneus longus and 
tibialis anterior. Specifically, an increase in compound muscle action (CMAP) was 
reported. In another case report, a 56-year-old woman who suffered from severity 
of symptoms of CTS received a treatment consisted of two US-guided perineural 
injections of 5 mL of PRP [51]. During follow-up at 3 and 6 months after the 
treatment, she revealed significant improvements in the distal motor and sensory 
latencies as well as the sensory nerve action potential and CMAP amplitudes of the 
median nerves. Finally, García de Cortazar et al. reported a case that described a 
patient with a section of the radial nerve [52]. Four months after the trauma and 
consequent surgery without positive response, serial intraneural infiltrations of 
PRP were conducted with US guidance. Eleven months after the first injection, 
EMG showed a complete reinnervation of the musculature of the radial nerve 
dependent.
5.2 PRP as adjuvant in surgery
In addition to the application of PRP in liquid form for neural infiltrations, its 
versatility allows it to formulate in different ways such as gel, scaffold or fibrin 
membrane to apply also in surgical interventions. (Figure 1). Kuffler et al. took 
advantage of these properties for patients with nerve gaps in their extremities [53]. 
In the surgical technique they conducted, collagen tubes filled with PRP formu-
lated as fibrin membrane were used to bridge the nerve gaps. Patients of this case 
series reached sensory and motor recovery across nerve gap, reduction of pain and 
functional recovery. Hibner et al. observed in a retrospective analysis the efficacy 
of injecting PRP around the pudendal nerve after a transgluteal decompression to 
enclose the nerve in NeuroWrapNerve Protector [54]. The pain of these patients 
who suffered from persistent pudendal neuralgia after neurolysis and transposition 
was significantly alleviated. This success was also achieved in patients with facial 
muscle and nerve deficit associated with benign parotid gland tumor [55]. In this 
randomized control study, Scala et al. observed significant improvements in several 
clinical parameters in the group of patients where PRP gel was applied during 
superficial parotidectomy.
6. Conclusion
6.1 Final considerations
Neuropathies are very challenging pathologies whose treatment options include 
conservative procedures as well as surgical interventions. In both cases, PRP is 
a promising and safe therapeutic tool that can be used as liquid formulation for 
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US-guided infiltrations or as fibrin scaffold for surgery. Its potential has been 
proved in diverse in vitro and in vivo studies, and there are constantly more treat-
ments based on this therapy in humans also. The use of this technique allows physi-
cians to take advantage of the biological processes required to achieve an optimal 
nerve repair and satisfactory clinical results.
6.2 Future directions
Although the PRP application for nerve pathologies is showing encouraging 
results and no negative side effects, apart from some painful episodes during 
injections, its use in these pathologies still has to be cautious. Although in some 
treatments normally the employed product has its importance, the way to use this 
product is also relevant to achieve a successful response. Elements such as a correct 
indication, an appropriate PRP elaboration and a suitable administration and appli-
cation procedures are essential for the success of these treatments. Further studies 
and cases are needed to increase the knowledge not only of PRP for neuropathies 
but also of nerve biology, and thus improve protocols as well as clinical outcomes.
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